甘精胰岛素与预混胰岛素分别联合口服降糖药治疗2型糖尿病患者的效果比较

Insulin glargine combined with oral hypoglycemic agents versus premixed insulin combined with oral hypoglycemic agents in treating patients with type 2 diabetes mellitus

目的 比较甘精胰岛素与预混胰岛素分别联合口服降糖药治疗2型糖尿病(T2DM)的效果.方法 84例T2DM患者随机分为A组与B组各42例.A组给予甘精胰岛素皮下注射联合口服降糖药阿卡波糖治疗,B组给予预混胰岛素联合阿卡波糖治疗.比较2组治疗前后血糖监测值、胰岛素用量和血糖达标情况.结果 2组治疗后空腹血糖(FBG)、餐后2h血糖(PBG)、糖化血红蛋白(HbA1c)水平均较本组治疗前显著下降(P<0.05).2组治疗后FBG、PBG、HbA1c控制达标率比较,差异均无统计学意义(P>0.05).A组胰岛素用量少于B组,低血糖发生率低于B组,差异均有统计学意义(P<0.05).2组心脑血管事件发生率比较,差异无统计学意义(P>0.05).结论 甘精胰岛素与预混胰岛素分别联合阿卡波糖均能有效控制血糖,但甘精胰岛素联合阿卡波糖方案能显著减少胰岛素用量,降低低血糖发生率.

Objective To compare the effect of insulin glargine combined with oral hypoglycemic agents and premixed insulin combined with oral hypoglycemic agents in treating patients with type 2 diabetes mellitus(T2DM).Methods A total of 84 patients with T2DM were randomly divided into group A and group B,with 42 cases in each group.Group A was treated with subcutaneous injection of insulin glargine combined with acarbose,while group B was treated with premixed insulin combined with acarboses.The value of blood glucose monitoring,insulin dosage and blood sugar achievement were compared before and after treatment between two groups.Results After treatment,the levels of fasting blood glucose(FBG),postprandial blood glucose(PBG)and glycosylated hemoglobin(HbA1c)in both groups were significantly lower than those before treatment(P<0.05).There were no significant differences in the control rate of FBG,PBG and HbA1c between the two groups after treatment(P>0.05).The dosage of insulin in group A was significantly less than that in group B,and the incidence rate of hypoglycemia was significantly lower than that in group B(P<0.05).There was no significant difference in the incidence rates of cardiovascular and cerebrovascular events between the two groups(P>0.05).Conclusion Both insulin glargine and premixed insulin combined with acarbose can effectively control blood sugar,but insulin glargine combined with acarbose can significantly reduce insulin dosage and the incidence rate of hypoglycemia.